The maintained guidance and solid ORLADEYO growth (+21% ex-Europe) are reassuring, but the stock is unlikely to move sharply on in-line results. The key catalyst to watch is the completion of navenibart Phase 3 enrollment by end of June 2026, which would de-risk the pipeline. The $70M upfront licensing deal provides a near-term cash buffer. Traders should monitor for any enrollment updates or guidance changes on the Q2 2026 earnings call.
BCRX drugs
BCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $8.83entry
- T+1 · 6mo ago +0.79%α +1.12% · $8.90
- T+5 · 6mo ago −0.34%α −1.47% · $8.80
- T+20 · 6mo ago −6.57%α −9.35% · $8.25
- T+60 · 4mo ago +1.70%α −0.36% · $8.98
Price Chart
How similar events traded
Executive Summary
BioCryst reported Q1 2026 ORLADEYO revenue of $148.3M (+11% y-o-y; +21% on a comparable ex-Europe basis), in line with the maintained FY2026 guidance of $625-645M. The GAAP net loss of $721.8M was driven by a $697.8M non-cash charge from the Astria acquisition, but non-GAAP operating profit was $54.2M. The company also announced a $70M upfront licensing deal for European navenibart rights, with up to $275M in milestones. Guidance was maintained, and the navenibart Phase 3 enrollment is on track to complete by June 2026.
Key Financial Metrics
Key Facts
- Q1 2026 ORLADEYO net revenue $148.3M, +11% reported y-o-y, +21% on a comparable basis excluding European revenue
- GAAP net loss of $721.8M driven by $697.8M non-cash acquired IPR&D charge from Astria acquisition
- Non-GAAP operating profit of $54.2M in Q1 2026
- Full-year 2026 ORLADEYO revenue guidance maintained at $625M-$645M; total revenue guidance maintained at $635M-$660M
- Licensing agreement with Neopharmed Gentili for European navenibart rights: $70M upfront, up to $275M milestones, plus 18%-30% tiered royalties
- Navenibart Phase 3 ALPHA-ORBIT enrollment on track to complete by end of June 2026; regulatory filing targeted by end of 2027
- Cash, equivalents, restricted cash and investments at March 31, 2026: $260.8M; pro-forma including post-quarter-end $70M license proceeds: $330.8M
- Company ended development of avoralstat (DME program) in Q1 2026
- Appointed Sandeep M. Menon as Chief Research and Development Officer in April 2026
Financial Impact
Q1 ORLADEYO revenue of $148.3M was in line with the maintained $625-645M annual guidance run-rate. The $70M upfront from the navenibart licensing deal strengthens the balance sheet.
Risk Factors
- Navenibart is still in Phase 3 and unapproved; regulatory or clinical setbacks could impair the $697.8M IPR&D asset
- GAAP net loss of $721.8M and accumulated deficit of $2.23B highlight ongoing cash burn despite non-GAAP profitability
- Secured term loan of $395.2M and royalty financing obligation of $447.5M represent significant leverage
- Competition in HAE from injectable therapies (Takhzyro, Haegarda) could pressure ORLADEYO growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003052 |
| Document: f8k_050626.htm | 0001171843-26-003052 |
| Document: 0001171843-26-003052-index-headers.html | 0001171843-26-003052 |
| Document: 0001171843-26-003052-index.html | 0001171843-26-003052 |
| Document: 0001171843-26-003052.txt | 0001171843-26-003052 |
| 8-K Data (Synthetic) | 0001171843-26-003052 |
Track record
20 reports on BCRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
- Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
- Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers